Edgar Filing: HELLUMS RHONDA LYNETTE

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â HELLUMS RHONDA LYNETTE

2. Date of Event Requiring Statement (Month/Day/Year)
02/01/2019

3. Issuer Name and Ticker or Trading Symbol
ARATANA THERAPEUTICS, INC. [PETX]

(Last)

(First)

(Middle)

C/O ARATANA THERAPEUTICS, INC.,Â 11400 TOMAHAWK CREEK PARKWAY, SUITE 340

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
CHIEF FINANCIAL OFFICER

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

LEAWOOD,Â KSÂ 66211

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	26,501	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	Â ⁽¹⁾	03/02/2024	Common Stock	25,000	$ 22.91	D	Â
Stock Option (Right to Buy)	Â ⁽²⁾	01/28/2025	Common Stock	2,650	$ 17.18	D	Â
Stock Option (Right to Buy)	Â ⁽³⁾	01/21/2026	Common Stock	6,700	$ 3.14	D	Â
Stock Option (Right to Buy)	Â ⁽⁴⁾	01/12/2027	Common Stock	4,100	$ 8.02	D	Â
Stock Option (Right to Buy)	Â ⁽⁵⁾	01/24/2028	Common Stock	14,700	$ 4.83	D	Â
Stock Option (Right to Buy)	Â ⁽⁶⁾	01/23/2029	Common Stock	15,100	$ 4.22	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
HELLUMS RHONDA LYNETTE C/O ARATANA THERAPEUTICS, INC. 11400 TOMAHAWK CREEK PARKWAY, SUITE 340 LEAWOOD,Â KSÂ 66211	Â	Â	Â CHIEF FINANCIAL OFFICER	Â

Signatures

/s/ John C. Ayres as Attorney-in-Fact for Rhonda Lynette Hellums		02/05/2019
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Fully vested as of March 3, 2018.
(2)	Fully vested as of January 29, 2019.
(3)	Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2017 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2020, subject to continued service with the Issuer through the applicable vesting dates.
(4)	Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2018 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2021, subject to continued service with the Issuer through the applicable vesting dates.
(5)	Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2019 and vests as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2022, subject to continued service with the Issuer through the applicable vesting dates.
(6)	Vests as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2020 and as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2023, subject to continued service with the Issuer through the applicable vesting dates.
Â Remarks: ExhibitÂ List:Â ExhibitÂ 24Â -Â PowerÂ ofÂ Attorney.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.